For all the attention that the iPhone’s encrypted storage and Whatsapp’s new end-to-end messaging encryption have gotten over the last few months---particularly from the US Justice Department---you'd ...

Lexicon inks a major collaborative deal and reports a narrow than expected quarterly loss. All in a day's work for a daily top-performer. So what: Although it was the smaller of the two catalysts, ...

A look at the shareholders of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies ...

Two companies have logged strong starts to the week in the biotech space so far, and both are moving on FDA driven catalysts. Here’s a look at these two companies, what’s moving them, and what’s next ...

Lexicon Pharmaceuticals has made progress in getting its lead drug Inpefa onto formularies and securing reimbursement agreements with insurers. Multiple studies support the cost efficacy of Inpefa for ...

An explosion in data volumes, proliferation of platforms, and evolving regulatory requirements has made effective monitoring of employee communications much more difficult. The remote and hybrid ...

Lexicon Pharmaceuticals (LXRX) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2019. This widely-known consensus ...

Shares of small-cap biotech Lexicon Pharmaceuticals (LXRX +1.65%) fell by nearly 15% during the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The ...

MIKE: Also, a listener of Lexicon Valley wrote recently in an iTunes review that every time he or she listens to an episode of this show, "I find myself committing whatever linguistic solipsism was ...

What: Shares of Lexicon Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development of small-molecule treatments to fight a host of diseases, rocketed higher by as much as ...